Becton, Dickinson and Company acquired Venclose, Inc.
December 01, 2021
Share
Becton, Dickinson and Company (NYSE:BDX) acquired Venclose, Inc. on December 2, 2021. The transaction is expected to be immaterial to BD's fiscal 2022 financial results.
Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Venclose, Inc. on December 2, 2021. Becton, Dickinson and Company used cash payments of $450 million relating to various strategic acquisitions executed as part of Becton's growth strategy, including Becton's acquisitions of Scanwell Health, Inc, Tissuemed, Ltd., and Venclose, Inc. J.P Morgan acted as the financial advisor to Venclose.
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows:
- medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.;
- diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.;
- clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc.
Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
BECTON, DICKINSON AND COMPANY 
